Skip to content

Efficacy of Traditional Persian Medicine Preparation Versus Artificial Saliva for Radiation Induced Xerostomia

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02854358
Enrollment
60
Registered
2016-08-03
Start date
2015-03-31
Completion date
2016-02-29
Last updated
2016-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancers, Xerostomia

Brief summary

Head and neck cancers(HNC) is one of the most common cancers worldwide. Xerostomia is one of the most common side effect of radiation therapy among patients with HNC. Mouth dryness significantly impairs patients' quality of life (QOL). HNC.Regarding to traditional use of A. digitata and M. sylvestris in addition to known their beneficial effects in recent studies, we decided to design a randomized, controlled clinical trial to try to evaluate efficacy of the these herbs in QOL of HNC patients with radiation induced xerostomia

Interventions

DRUGmixed powder of A. digitata and M. sylvestris
DRUGHypozalix spray (artificial saliva)

Hypozalix spray (artificial saliva)

Sponsors

Shahid Beheshti University of Medical Sciences
CollaboratorOTHER
Shiraz University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* patients with head and neck cancer who had grade 1 and 2 xerostomia (based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0) and finished radiotherapy at least two months before the study(22).

Exclusion criteria

* history of connective tissue disorder (e.g., Sjogren) other medical causes of xerostomia (such as diabetes, bowel and renal diseases), using antidepressants drugs, recurrence of cancer, end stage cancer, pregnancy, lactation history of hypersensitivity or allergy to A. digitata and M. sylvestris

Design outcomes

Primary

MeasureTime frameDescription
changes in patients' quality of life4 weekschanges in patients' quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire\|(EORTC QLQ-H&N 35)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026